The ocular drug discovery arena has undergone a significant improvement in the last few years culminating in the FDA approvals of 8 new drugs. However, despite a large number of drugs, generics, and combination products available, it remains an urgent need to find breakthrough strategies and therapies for tackling ocular diseases. Targeting the adenosinergic system may represent an innovative strategy for discovering new ocular therapeutics. This review focused on the recent advance in the field and described the numerous nucleoside and non-nucleoside modulators of the four adenosine receptors (ARs) used as potential tools or clinical drug candidates.

中文翻译：

---

腺苷受体作为治疗眼部疾病的有希望的靶点

在过去几年中，眼部药物发现领域取得了显着进步，最终获得 FDA 批准的 8 种新药。然而，尽管有大量的药物、仿制药和组合产品可供使用，但仍然迫切需要找到解决眼部疾病的突破性策略和疗法。针对腺苷能系统可能代表了一种发现新眼部疗法的创新策略。本综述重点介绍了该领域的最新进展，并描述了用作潜在工具或临床候选药物的四种腺苷受体 (AR) 的众多核苷和非核苷调节剂。